How Ambulatory Surgery Centers Are Valued
ASC valuation is one of the more structured corners of healthcare M&A, the buyer universe is concentrated, the methodology is consistent, and the comparable transaction set is dense. The challenge is that the spread between a 5x single-center deal and a 14x platform deal is enormous, and most operators significantly under-or over-estimate where their center sits on that curve.
Single-Center vs. Platform Pricing
Single-center, single-specialty ASCs with $2-5M EBITDA typically sell at platform-tier earnings multiples to a regional acquirer or hospital system. Buyers underwrite case volume, payer mix, and physician partner stability. Centers without strong physician syndication or with concentrated case volume from 1-2 surgeons price at the bottom of this range.
Multi-specialty single-center ASCs with broader case mix, orthopedic, GI, pain, ENT, ophthalmology, and $4-10M EBITDA price at platform-tier earnings multiples. The premium reflects payer-mix diversification and reduced single-specialty risk.
Multi-center platforms (2-10 centers) trade at platform-tier earnings multiples when sold to a national strategic. The platform premium captures management infrastructure, payer contracting leverage, and the ability to bolt on additional centers. PE firms specifically pay platform multiples for management teams that can execute roll-ups, not just for the existing centers.
Large PE-backed platforms , USPI (Tenet), SCA (Surgery Care Affiliates, now Optum), Surgery Partners (SGRY), and the large regional networks, trade at platform-tier earnings multiples. SGRY, the only pure-play public ASC operator, has historically traded in the 10-13x earnings multiple range and serves as the de facto public comp anchor for ASC platform transactions.
Specialty Mix Drives the Multiple
Not all case mix is created equal. Orthopedic-focused ASCs command the highest multiples in the asset class because of high case acuity, favorable reimbursement (total joints, spine, sports medicine), and the migration of inpatient ortho to outpatient settings. An ortho-heavy ASC will routinely trade 1-2 turns above a comparable multi-specialty center.
GI-focused centers trade at steady, predictable multiples, usually platform-tier earnings multiples single-center. Volume is high, reimbursement is well-defined, and physician relationships are durable, but the case acuity ceiling caps the upside.
Pain management and interventional spine centers carry both upside (favorable reimbursement, low capital intensity) and risk (payer pushback, utilization review). Multiples are wider, platform-tier earnings multiples, depending on case mix and payer contracts.
Multi-specialty centers with no dominant specialty trade at the broad platform-tier earnings multiples single-center range, with the multiple driven more by payer mix and physician structure than by case acuity.
Certificate of Need (CON) States Trade at a Premium
ASCs in Certificate of Need (CON) states, New York, New Jersey, Maryland, North Carolina, South Carolina, Georgia, Tennessee, Virginia, and others, trade at meaningful premiums because the regulatory barrier to entry protects existing operators from new competition. A center in a CON state with a defensible service area can command 1-2 turns above the same center in a non-CON state. This is one of the most material valuation factors that owners frequently undervalue.
Physician Syndication and Roll-Over Equity
ASC M&A is structurally different from other healthcare deals because of physician syndication. Most ASCs are owned in some combination of management company (often the ASC operator itself), hospital partner, and physician partners. When a center is sold to a strategic, the physician partners typically roll over a meaningful portion of their equity into the acquirer's platform, both because the strategic wants to preserve physician case loyalty and because the physicians want to stay invested in upside.
This structure has two valuation implications. First, the "headline" transaction multiple often reflects the management-company stake; physician roll-over deals can be structured at slightly different valuations. Second, deals where physician partners refuse to roll equity (because they're close to retirement or don't trust the buyer) consistently price 1-2 turns below market because the strategic has to underwrite case attrition risk.
Operational Drivers That Move the Multiple
Case mix index and average revenue per case are the cleanest profitability indicators. ASCs with average net revenue per case above $3,500 (driven by ortho, total joints, complex spine) trade at materially higher multiples than centers averaging $1,500-2,000 per case (GI, ophthalmology).
Payer mix drives both EBITDA and the multiple applied to it. Centers with strong commercial payer mix (60%+ commercial), favorable in-network rates with major carriers, and limited Medicaid exposure command premium pricing. Out-of-network revenue adds yield but is treated cautiously by acquirers because of reimbursement volatility.
Physician partner stability , the share of cases coming from physicians with at least 5 years of utilization history, ideally with equity in the center, is what buyers ultimately underwrite. Centers where 3 surgeons drive 70% of cases without roll-over equity are the highest-risk profile and price accordingly.
Hospital-system competition in the service area meaningfully impacts multiples. ASCs operating in markets where local hospital systems are aggressively acquiring physician practices (and therefore steering cases away from independent ASCs) trade at a discount.